Edition:
United Kingdom

Allergan plc (AGN.N)

AGN.N on New York Stock Exchange

182.95USD
15 Oct 2018
Change (% chg)

-- (--)
Prev Close
$182.95
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
480,993
52-wk High
$206.78
52-wk Low
$142.83

Latest Key Developments (Source: Significant Developments)

Allergan Launches Personalized Study Approach For Clinical Research Programs In Inflammatory Bowel Disease
Friday, 5 Oct 2018 

Oct 5 (Reuters) - Allergan plc ::ALLERGAN LAUNCHES PERSONALIZED STUDY APPROACH FOR CLINICAL RESEARCH PROGRAMS IN INFLAMMATORY BOWEL DISEASE.ALLERGAN - PROGRAMS WILL EVALUATE SAFETY AND EFFICACY OF BRAZIKUMAB AND POTENTIAL CORRELATION BETWEEN BIOMARKERS AND PATIENT OUTCOMES WITH BRAZIKUMAB.  Full Article

Allergan Receives FDA Clearance To Treat Area Below Jawline With Coolsculpting
Thursday, 4 Oct 2018 

Oct 4 (Reuters) - Allergan plc ::ALLERGAN RECEIVES FDA CLEARANCE TO TREAT AREA BELOW THE JAWLINE WITH COOLSCULPTING®.ALLERGAN PLC - FDA CLEARANCE WAS EXPANDED TO INCLUDE PATIENTS WITH A BMI OF UP TO 46.2 WHEN TREATING SUBMENTAL AND SUBMANDIBULAR AREAS.  Full Article

Almirall Receives FDA Approval For Seysara (Sarecycline)
Tuesday, 2 Oct 2018 

Oct 2 (Reuters) - Almirall SA ::RECEIVES FDA APPROVAL FOR SEYSARA (SARECYCLINE).WILL BE LAUNCHING SEYSARA IN JANUARY 2019 IN US MARKET AND EXPECTS PEAK SALES OF SEYSARA BETWEEN $150 MILLION TO $200 MILLION.SEYSARA TREATS INFLAMMATORY LESIONS OF ACNE IN PATIENTS 9 YEARS OF AGE AND OLDER.NEW PRODUCT COMES FROM ALLERGAN U.S. MEDICAL DERMATOLOGY ACQUISITION AND ITS APPROVAL IS AHEAD OF PLAN.  Full Article

Allergan Announces FDA Acceptance Of Supplemental New Drug Application For Vraylar
Wednesday, 26 Sep 2018 

Sept 26 (Reuters) - Allergan plc ::ALLERGAN ANNOUNCES FDA ACCEPTANCE OF SUPPLEMENTAL NEW DRUG APPLICATION FOR VRAYLAR® (CARIPRAZINE).ALLERGAN ANNOUNCES FDA ACCEPTANCE OF SUPPLEMENTAL NEW DRUG APPLICATION FOR VRAYLAR® (CARIPRAZINE).ALLERGAN PLC - APPLICATION SEEKS TO EXPAND VRAYLAR INDICATION TO INCLUDE TREATMENT OF BIPOLAR DEPRESSION.ALLERGAN PLC - CARIPRAZINE WAS GENERALLY WELL TOLERATED IN TRIALS.  Full Article

Almirall Closes Deal With Allergan, Buys Its US Medical Dermatology Portfolio
Friday, 21 Sep 2018 

Sept 21 (Reuters) - Almirall SA ::SAYS CLOSES AGREEMENT WITH ALLERGAN AND ACQUIRES ITS US MEDICAL DERMATOLOGY PORTFOLIO.SAYS TRANSACTION HAS BEEN CLOSED FOR A CASH CONSIDERATION OF $550 MLN.DEAL ALSO CONTEMPLATES POSSIBLE EARN-OUT, UP TO $100 MILLION AND PAYABLE IN Q1/2022, DEPENDING ON BUSINESS PERFORMANCE.SAYS AGREEMENT FOR ACQUISITION IS IMMEDIATELY EPS ACCRETIVE FROM 2019 ONWARDS.DEAL WAS FUNDED THROUGH BRIDGE LOAN FROM BBVA AND SANTANDER BANKS, LEVERAGE WILL NOT EXCEED 2.5 TIMES EBITDA.TO FOCUS ON ITS MEDICAL DERMATOLOGY FRANCHISE, CO WILL LOOK AT STRATEGIC OPTIONS FOR ITS AESTHETIC BUSINESS.  Full Article

Allergan Highlights Key Growth Drivers For Medical Aesthetics
Friday, 14 Sep 2018 

Sept 14 (Reuters) - Allergan plc ::ALLERGAN HIGHLIGHTS KEY GROWTH DRIVERS FOR MEDICAL AESTHETICS.ALLERGAN - EXPECTS TO LAUNCH 1 TO 2 PRODUCTS PER YEAR FROM 2018 TO 2025 ACROSS FACIAL AESTHETICS, BODY CONTOURING AND PLASTIC AND REGENERATIVE MEDICINE.  Full Article

Allergan Says Paul Bisaro To Retire from Board
Wednesday, 29 Aug 2018 

Aug 29 (Reuters) - Allergan plc ::ALLERGAN CONTINUES BOARD REFRESHMENT PROCESS.ALLERGAN PLC - PAUL BISARO WILL BE RETIRING FROM ITS BOARD OF DIRECTORS, AS PART OF COMPANY'S ONGOING BOARD REFRESHMENT PROCESS.ALLERGAN PLC - BISARO SERVED ON BOARD SINCE 2007 WHEN HE JOINED WATSON LABORATORIES AS ITS CEO.ALLERGAN - POST RETIREMENT OF BISARO & PREVIOUSLY ANNOUNCED RETIREMENT OF FRED WEISS & ADDITION OF MICHAEL GREENBERG, CO'S BOARD WILL HAVE 11 MEMBERS.  Full Article

Allergan Receives CRL From FDA For Ulipristal Acetate New Drug Application
Tuesday, 21 Aug 2018 

Aug 21 (Reuters) - Allergan plc ::ALLERGAN RECEIVES COMPLETE RESPONSE LETTER FROM THE U.S. FOOD AND DRUG ADMINISTRATION FOR ULIPRISTAL ACETATE NEW DRUG APPLICATION.ALLERGAN PLC - COMPLETE RESPONSE LETTER FROM FDA INDICATES IT IS NOT ABLE TO APPROVE ULIPRISTAL ACETATE NDA IN ITS CURRENT FORM.ALLERGAN PLC - COMPLETE RESPONSE LETTER FROM FDA IS REQUESTING ADDITIONAL INFORMATION.ALLERGAN PLC - IN COMPLETE RESPONSE LETTER FROM FDA, FDA CITED SAFETY CONCERNS REGARDING ESMYA POST-MARKETING REPORTS OUTSIDE UNITED STATES.ALLERGAN - GOT CRL FROM U.S. FDA IN RESPONSE TO NDA FOR ULIPRISTAL ACETATE FOR TREATMENT OF ABNORMAL UTERINE BLEEDING IN WOMEN WITH UTERINE FIBROIDS.  Full Article

Allergan Appoints Neurobiology Expert Michael Greenberg To Its Board Of Directors
Wednesday, 8 Aug 2018 

Aug 8 (Reuters) - Allergan plc ::ALLERGAN APPOINTS NEUROBIOLOGY EXPERT MICHAEL E. GREENBERG, PHD TO ITS BOARD OF DIRECTORS AS PART OF ACTIVE BOARD REFRESHMENT PROCESS.ALLERGAN PLC - FRED G. WEISS WILL RETIRE FROM ALLERGAN BOARD EFFECTIVE OCTOBER 2018.ALLERGAN PLC - FOLLOWING CHANGES, BOARD WILL CONTINUE TO HAVE 12 MEMBERS OF WHICH 10 ARE INDEPENDENT.  Full Article

Allergan And Editas Medicine Announce To Jointly Develop Crispr Genome Editing Experimental Medicine Edit-101
Monday, 6 Aug 2018 

Aug 6 (Reuters) - Allergan plc ::ALLERGAN AND EDITAS MEDICINE ANNOUNCE EXERCISE OF OPTIONS TO JOINTLY DEVELOP CRISPR GENOME EDITING EXPERIMENTAL MEDICINE EDIT-101.EXERCISED OPTION TO DEVELOP & COMMERCIALIZE EDIT-101 GLOBALLY FOR TREATMENT OF LCA10.HAS PAID EDITAS MEDICINE A FEE OF $15 MILLION IN CONJUNCTION WITH EXERCISE OF ITS OPTION.ADDITIONALLY, EDITAS MEDICINE HAS EXERCISED ITS OPTION TO CO-DEVELOP, SHARE EQUALLY IN PROFITS AND LOSSES FROM EDIT-101 IN U.S..EDITAS MEDICINE ELIGIBLE TO RECEIVE ADDITIONAL $25 MILLION FROM ALLERGAN UPON ACCEPTANCE OF IND APPLICATION FOR EDIT-101 BY FDA.  Full Article

UPDATE 6-Pfizer to replace longtime CEO Read with veteran Bourla

* Pfizer shares have risen 160 pct during Read's tenure (Adds background on Read and Bourla; updates shares)